secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2026-01-30T23:59:59+00:00
Accession:  0001517022-26-000008
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 2.03, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia leases 43,474 sq ft in Waltham for HQ; amends CEO/CFO severance
----------------------------------------------------------------------

- Leases 28,518 sq ft office + 14,956 sq ft lab at 180 Third Ave, Waltham, MA; HQ relocation planned for Sept 2026.
- Annual office rent starts at $898,317, lab rent at $1,046,920; initial 84-month term with 5-year renewal option.
- Security deposit of $810,515 in irrevocable letter of credit; landlord pays all work costs.
- CEO John Butler severance: 12 months salary (non-CIC) or 24 months salary + 200% bonus (CIC); full equity vest on CIC.
- CFO Erik Ostrowski severance: 12 months salary (non-CIC) or 12 months salary + 100% bonus (CIC); full vest of pre-2026 grants on CIC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702226000008/0001517022-26-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702226000008/akba-20260127.htm
  HTML page:      https://secwatch.observer/filing/0001517022-26-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer